Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug362 | BCG-Denmark Wiki | 0.58 |
drug3616 | Woebot Substance Use Disorder Wiki | 0.50 |
drug360 | BCG vaccine (Freeze-dried) Wiki | 0.50 |
Navigate: Correlations HPO
There are 4 clinical trials
The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction. The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users
Description: measurement of the difference in drugs consumption caused by containment (delta)
Measure: Evolution of consumption Time: 1 dayDescription: measurement of the difference in drugs consumption caused by containment (delta)
Measure: Evolution of consumption Time: 1 month after confinmantDescription: number of drug users referred to care (%)
Measure: health care access Time: 1 dayDescription: number of drug users referred to care (%)
Measure: health care access Time: 1 month after confinmantThis study seeks to gather data and insight on epidemiologic trends of loneliness and other behaviors in the wake of the CDC recommended "social distancing" during the COVID-19 pandemic. The objective of this study is to use a cross-sectional survey to assess the impact of COVID-19's associated recommendations (social distancing, self-isolation, and self-quarantine) on loneliness and psychosocial symptomatology (depression, anxiety, substance abuse) on young adults (18-35 years old).
Description: University of California Los Angeles ( UCLA) Loneliness Scale is a 20-item self-report questionnaire that evaluates subjective feelings of loneliness and social isolation. Participants rate items on a 4-point Likert scale ranging from 1 (never) to 4 (often).Items are summed to create a score that can range from 20-80, higher scores being indicative of greater loneliness.
Measure: Loneliness as evaluated by the UCLA loneliness scale Time: Day 1Description: Alcohol Use Disorder Identification Test (AUDIT) is a 10-item self-reported questionnaire used to identify individuals whose alcohol consumption could be hazardous for their health. Participants rate items in a 5-point Likert scale, indicating amount (0 to 10 drinks or more), frequency (never to daily or almost daily), and indication of problems caused by alcohol (yes or no). Items were summed up to create a score that can range from 0 to 50. A score of 1 to 7 indicates low risk consumption, whereas a score of 8-15 suggests risky or hazardous drinking, a score of more than 15 is likely to indicate high-risk drinking and alcohol dependence.
Measure: Alcohol Use as evaluated by the AUDIT Time: Day 1Description: The Drug Abuse Screening Test (DAST-10) is a 10-item self-reported screening test that provides a quantitative index of the degree of consequences related to drug abuse. Participants rate items yes or no, positive responses corresponding to 1 point. Items are summed up to create a score that can range from 0-10. A score of 1-2 represents risky behaviors related to drugs, 3-5 represents moderate problems, 6-8 represents substantial problems, and 9-10 represents severe problems.
Measure: Drug Use as evaluated by the DAST-10 Time: Day 1Description: The General Anxiety Disorder Scale (GAD- 7) is a 7- item self-reported screening tool that assess presence and severity of Generalized Anxiety Disorder. Participants rated frequency of problems in a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Items are summed up to create a score with scores of 5, 10, and 15 being the cut-off points for mild, moderate and severe anxiety, respectively.
Measure: Anxiety as evaluated by GAD-7 Time: Day 1Description: The Center for Epidemiologic Studies Depression scale (CES-D-10) is a 10-item self-reported measure that assesses the frequency of symptoms of depression. Participants rate frequency of symptoms in a 4-point Likert scale from 0 (rare or none of the time) to 3 (most or almost all the time). Items are summed up to create a score that ranges from 0 to 30, with higher scores representing greater depressive symptoms. A score of 16 or more represents clinical depression.
Measure: Depression as assessed by CES-D-10 Time: Day 1The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Description: Range from 0-100 (no pain to worst pain imaginable)
Measure: Pain rating Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-27, higher scores indicate greater levels of depression
Measure: Patient Health Questionnaire-9 (PHQ-9) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-21, higher scores indicate greater levels of anxiety
Measure: General Anxiety Disorder-7 (GAD-7) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Range from 8 to 32, with higher values indicating higher satisfaction
Measure: Client Satisfaction Questionnaire (CSQ) Time: Post-treatment (8 weeks from baseline)The overarching objective of the proposed project is to test the relative clinical efficacy of CBD isolate, full-spectrum CBD oil, and placebo in in reducing COVID-Induced stress, anxiety, depression, anger, and sleep disturbance.
Description: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 0-BaselineDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 1-TreatmentDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 2-TreatmentDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 3-TreatmentDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Weeks 4-TreatmentDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 5-TreatmentDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 6-TreatmentDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 7-Follow-upDescription: This measure is a 23-item patient-rated emotional distress symptom scale consisting of 3 sub-factors (Depression, Anxiety, and Anger). Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Emotional Distress Index Time: Week 8-Follow-upDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 0-BaselineDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 1-TreatmentDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 2-TreatmentDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 3-TreatmentDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 4-TreatmentDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 5-Follow-upDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Depression Scale Time: Week 6-Follow-upDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 0 BaselineDescription: This measure is an 8-item patient-rated depression symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 1-TreatmentDescription: This measure is a 7-item patient-rated anxiety symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 2-TreatmentDescription: This measure is a 7-item patient-rated anxiety symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 3-TreatmentDescription: This measure is a 7-item patient-rated anxiety symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 4-TreatmentDescription: This measure is a 7-item patient-rated anxiety symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 5-Follow-upDescription: This measure is a 7-item patient-rated anxiety symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anxiety Scale Time: Week 6-Follow-upDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 0 BaselineDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 1 TreatmentDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 2 TreatmentDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 3 TreatmentDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 4 TreatmentDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 5 Follow-upDescription: This measure is an 8-item patient-rated anger symptom scale. Each symptom is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Anger Scale Time: Week 6 Follow-upDescription: This measure is an 8-item patient-rated index of alcohol-related problems. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 0 BaselineDescription: This measure is an 8-item patient-rated index of alcohol-related problems. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 1 TreatmentDescription: This measure is an 8-item patient-rated index of alcohol-related problems. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 2 TreatmentDescription: This measure is an 8-item patient-rated index of alcohol-related problems. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Never) to 5 (Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 3 TreatmentDescription: This measure is an 8-item patient-rated index of substance use severity. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Almost Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 4 TreatmentDescription: This measure is an 8-item patient-rated index of substance use severity. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Almost Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 5 Follow-upDescription: This measure is an 8-item patient-rated index of substance use severity. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Almost Always).
Measure: PROMIS Alcohol Negative Consequences Scale Time: Week 6 Follow-upDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 0 BaselineDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 1 TreatmentDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 2 TreatmentDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 3 TreatmentDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 4 TreatmentDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 5 Follow-upDescription: This measure is an 8-item patient-rated index of sleep disturbance. Each item is rated over a 7-day period on a 5-point scale ranging from 1 (Not at all) to 5 (Very Much).
Measure: PROMIS Sleep Disturbance Scale Time: Week 6 Follow-upDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 0 BaselineDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 1 TreatmentDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 2 TreatmentDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 3 TreatmentDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 4 TreatmentDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 5 Follow-upDescription: This measure is a 12-item author-constructed patient-rated index of COVID-19 Coping Self-Efficacy
Measure: COVID-19 Coping Self-Efficacy Time: Week 6 Follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports